High-risk neuroblastoma (NBL) Program in Pharmaceutical Benefits Scheme (PBS) 012-25070740
Expand allThis document outlines details of PBS-subsidised eflornithine for patients with high-risk neuroblastoma (NBL).
High-risk NBL and listing dates
High-risk NBL is a severe form of neuroblastoma, a cancer that develops from immature nerve cells and most commonly affects infants and young children. It typically arises in and around the adrenal glands but can also develop in the neck, chest, abdomen or spine.
Listing date: eflornithine - 1 August 2025.
See Written Authority Required Drugs for more details.
Enquiries
Transfer enquiries about prescription arrangements to PBS Complex Drugs Programs and choose the option relevant to the condition being treated.
The Resources page contains:
- application forms
- contact details
- FAQs from Service Officers
- restriction and item codes
- the PBS schedule
- Services Australia website link
Related links
Online Pharmaceutical Benefits Scheme (PBS) Authorities System (OPA System)
Processing an existing Authority request in the Pharmaceutical Benefits Scheme (PBS)
Processing and National Demand Allocation (PaNDA)
Processing Complex Authority Required Listings
Processing Delayed Assessment requests in the Pharmaceutical Benefits Scheme (PBS)
Processing new Authority requests in the Pharmaceutical Benefits Scheme (PBS)
Written Authority Required Drugs